CAH
FY2026 Q3 · Calendar Q2 2026
Cardinal Health, Inc.
Cardinal Health delivered strong Q3 FY2026 results with non-GAAP EPS up 35% to $3.17, beating consensus by 13.6%, driven by Specialty Solutions and at-Home/Nuclear growth. Management raised full-year EPS and free cash flow guidance. However, revenue of $60.9B missed the $62.1B consensus by 1.9%, SG&A investment accelerated, and a $184M Navista goodwill impairment underscored integration risk. The stock fell 4.9% on 3x normal volume despite the beat and guide raise, then recovered 2.0% in subsequent sessions. The investment thesis rests on Specialty platform expansion, theranostics capacity scaling, and GLP-1 demand tailwinds, offset by tariff uncertainty and margin pressure from rising operating costs.
EPS surprise+13.6%
Market move-4.9%
